O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 8.65 GBX 1.76%
Market Cap: 34.9m GBX
Have any thoughts about
Ondine Biomedical Inc?
Write Note

Ondine Biomedical Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ondine Biomedical Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Operating Income
-CA$14.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Operating Income
-$2.3m
CAGR 3-Years
48%
CAGR 5-Years
49%
CAGR 10-Years
14%
Profound Medical Corp
TSX:PRN
Operating Income
-$33.1m
CAGR 3-Years
-9%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Operating Income
-CA$12.5m
CAGR 3-Years
-86%
CAGR 5-Years
-25%
CAGR 10-Years
-19%
Theralase Technologies Inc
XTSX:TLT
Operating Income
-CA$4.4m
CAGR 3-Years
1%
CAGR 5-Years
-2%
CAGR 10-Years
-12%
MedMira Inc
XTSX:MIR
Operating Income
-CA$2.6m
CAGR 3-Years
-141%
CAGR 5-Years
-15%
CAGR 10-Years
3%
No Stocks Found

Ondine Biomedical Inc
Glance View

Market Cap
34.9m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
4.24 GBX
Overvaluation 51%
Intrinsic Value
Price
O

See Also

What is Ondine Biomedical Inc's Operating Income?
Operating Income
-14.8m CAD

Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Operating Income amounts to -14.8m CAD.

What is Ondine Biomedical Inc's Operating Income growth rate?
Operating Income CAGR 1Y
21%

Over the last year, the Operating Income growth was 21%.

Back to Top